While the insulinotropic effect of GLP-1 in T2D patients is relatively more preserved compared to GIP4,13,14, several lines of evidence suggests that prevention of GIP degradation may potentially contribute to the antihyperglycemic effects of DPP-IV inhibitors. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.